The objective of this study is to understand if Rivaroxaban can improve treatment
satisfaction of Warfarin patients and assess the safety and effectiveness of Xarelto in real
A total of 725 patients are to be enrolled and followed for a 6 months.period. QOL survey
will be conducted at month 0, 3, 6 using ACTS/TSQM.
This study is categorized as a regulatory post-marketing surveillance in Japan, and it is a
local prospective and observational study of patients who have received Xarelto for SPAF.